Advertisement

Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia

  • Chun-Li Wang
  • Victor Chien-Chia Wu
  • Cheng-Hung Lee
  • Chang-Fu Kuo
  • Yu-Ling Chen
  • Pao-Hsien Chu
  • Shao-Wei Chen
  • Ming-Shien Wen
  • Lai-Chu See
  • Shang-Hung ChangEmail author
Article
  • 83 Downloads

Abstract

Patients with thrombocytopenia were excluded from major clinical trials that investigated non-vitamin-K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation (AF). The aim of this study was to evaluate the effectiveness and safety of NOAC versus warfarin in AF patients with thrombocytopenia. From 2010 to 2017, a cohort study based on electronic medical records of a multi-center healthcare provider in Taiwan and included 8239 anticoagulated AF patients (age 77.0 ± 7.3 years, 48.0% female). Patients were divided into two subgroups: 7872 patients with a normal platelet count and 367 patients (4.4%) with thrombocytopenia, which was defined as a platelet count less than 100 × 103/µL. We performed Cox proportional hazard analyses to compare the risks of ischemic stroke or systemic embolism (IS/SE), major bleeding, and death between NOAC and warfarin therapies in patients with a normal platelet count and those with thrombocytopenia, respectively. In patients with a normal platelet count, NOAC therapy (n = 4904) was associated with a significantly lower risk of major bleeding, with no difference in the risk of IS/SE or death when compared with warfarin therapy (n = 2968). In patients with thrombocytopenia, NOAC therapy (n = 181) was associated with a lower tendency for major bleeding (aHR 0.45, 95% CI 0.16–1.14) with no significant difference in IS/SE (aHR 0.94, 95% CI 0.29–2.91) or death (aHR 0.95, 95% CI 0.46–1.95) when compared with warfarin therapy (n = 186). NOAC therapy is a reasonable choice for stroke prevention in AF patients with thrombocytopenia.

Keywords

Atrial fibrillation Bleeding Stroke Oral anticoagulation Thrombocytopenia Warfarin 

Notes

Acknowledgements

The authors thank the statistical assistance and wish to acknowledge the support of the Maintenance Project of the Center for Big Data Analytics and Statistics (Grant CLRPG3D0044) at Chang Gung Memorial Hospital for study design and monitor, data analysis and interpretation. This study is based in part on data from the Chang Gung Research Database provided by Chang Gung Memorial Hospital. The interpretation and conclusions contained herein do not represent the position of Chang Gung Memorial Hospital.

Funding

This work was funded by research grants from the Chang Gung Memorial Hospital, Linkou, Taiwan (CORPG3G0271, CMRPG3E2101, CMRPG3G2031, CLRPG3D0045).

Compliance with ethical standards

Conflict of interest

All authors have no conflict of interests to declare.

Supplementary material

11239_2018_1792_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 16 KB)

References

  1. 1.
    Fernández CS, Formiga F, Camafort M, Rodrigo JMC, Díez-Manglano J, Reino AP, Tiberio G, Mostaza JM (2015) Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord.  https://doi.org/10.1186/s12872-015-0137-7 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Mojadidi MK, Galeas JN, Goodman-Meza D, Eshtehardi P, Msaouel P, Kelesidis I, Zaman MO, Winoker JS, Roberts SC, Christia P, Zolty R (2016) Thrombocytopaenia as a prognostic indicator in heart failure with reduced ejection fraction. Heart Lung Circ 25(6):568–575.  https://doi.org/10.1016/j.hlc.2015.11.010 CrossRefPubMedGoogle Scholar
  3. 3.
    Slichter SJ (2004) Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 18(3):153–167CrossRefGoogle Scholar
  4. 4.
    Uhl L, Assmann SF, Hamza TH, Harrison RW, Gernsheimer T, Slichter SJ (2017) Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial. Blood 130(10):1247–1258.  https://doi.org/10.1182/blood-2017-01-757930 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Baelum JK, Moe EE, Nybo M, Vinholt PJ (2017) Venous thromboembolism in patients with thrombocytopenia: risk factors, treatment, and outcome. Clin Appl Thromb/Hemost 23(4):345–350.  https://doi.org/10.1177/1076029615613158 CrossRefGoogle Scholar
  6. 6.
    Caro J, Navada S (2018) Safety of anticoagulation in patients with atrial fibrillation and MDS/AML complicated by thrombocytopenia: an unresolved challenge: can they be managed? A report of three cases and literature review. Am J Hematol 93(5):E112–E114.  https://doi.org/10.1002/ajh.25045 CrossRefPubMedGoogle Scholar
  7. 7.
    Matzdorff A, Beer JH (2013) Immune thrombocytopenia patients requiring anticoagulation—maneuvering between Scylla and Charybdis. Semin Hematol 50(Suppl 1):S83–S88.  https://doi.org/10.1053/j.seminhematol.2013.03.020 CrossRefPubMedGoogle Scholar
  8. 8.
    Thachil J, Callaghan T, Martlew V (2010) Thromboembolic events are not uncommon in patients with immune thrombocytopenia. Br J Haematol 150(4):496–497.  https://doi.org/10.1111/j.1365-2141.2010.08234.x CrossRefPubMedGoogle Scholar
  9. 9.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 361(12):1139–1151.  https://doi.org/10.1056/NEJMoa0905561 CrossRefPubMedGoogle Scholar
  10. 10.
    Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104.  https://doi.org/10.1056/NEJMoa1310907 CrossRefPubMedGoogle Scholar
  11. 11.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992.  https://doi.org/10.1056/NEJMoa1107039 CrossRefPubMedGoogle Scholar
  12. 12.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891.  https://doi.org/10.1056/NEJMoa1009638 CrossRefPubMedGoogle Scholar
  13. 13.
    Mekaj YH, Mekaj AY, Duci SB, Miftari EI (2015) New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag 11:967–977.  https://doi.org/10.2147/tcrm.S84210 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799–808.  https://doi.org/10.1056/NEJMoa1302507 CrossRefPubMedGoogle Scholar
  15. 15.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962.  https://doi.org/10.1093/eurheartj/ehw210 CrossRefPubMedGoogle Scholar
  16. 16.
    January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64(21):e1–e76.  https://doi.org/10.1016/j.jacc.2014.03.022 CrossRefPubMedGoogle Scholar
  17. 17.
    Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbuchel H (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330–1393.  https://doi.org/10.1093/eurheartj/ehy136 CrossRefPubMedGoogle Scholar
  18. 18.
    Chang Gung Memorial Hospital (2018) About CGMH—service overview. Chang Gung Medical Foundation. https://www.cgmh.org.tw/cgmh/about/about_04.htm. Accessed 14 July 2018
  19. 19.
    Lai YF, Goh DYT, How SY, Lee KY, Tham VWP, Kong MC, Tan CW, Ng HJ (2017) Safety and efficacy of warfarin in patients with moderate thrombocytopenia. Thromb Res 155:53–57.  https://doi.org/10.1016/j.thromres.2017.05.007 CrossRefPubMedGoogle Scholar
  20. 20.
    Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364(9):806–817.  https://doi.org/10.1056/NEJMoa1007432 CrossRefPubMedGoogle Scholar
  21. 21.
    Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji RA, Wells PS, Wu C, Nazi I, Crowther MA (2016) Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. J Thromb Haemost 14(6):1206–1210.  https://doi.org/10.1111/jth.13330 CrossRefPubMedGoogle Scholar
  22. 22.
    Warkentin TE, Pai M, Linkins LA (2017) Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood 130(9):1104–1113.  https://doi.org/10.1182/blood-2017-04-778993 CrossRefPubMedGoogle Scholar
  23. 23.
    Ezekwudo DE, Chacko R, Gbadamosi B, Batool S, Gaikazian S, Warkentin TE, Sheppard JI, Jaiyesimi I (2017) Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature. Exp Hematol Oncol.  https://doi.org/10.1186/s40164-017-0080-7 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Janion-Sadowska A, Papuga-Szela E, Lukaszuk R, Chrapek M, Undas A (2018) Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and thrombocytopenia. J Cardiovasc Pharmacol.  https://doi.org/10.1097/fjc.0000000000000607 CrossRefPubMedGoogle Scholar
  25. 25.
    Halvorsen S, Ghanima W, Fride Tvete I, Hoxmark C, Falck P, Solli O, Jonasson C (2017) A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother 3(1):28–36.  https://doi.org/10.1093/ehjcvp/pvw031 CrossRefPubMedGoogle Scholar
  26. 26.
    Chan YH, See LC, Tu HT, Yeh YH, Chang SH, Wu LS, Lee HF, Wang CL, Kuo CF, Kuo CT (2018) Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J Am Heart Assoc 7(8):e008150.  https://doi.org/10.1161/jaha.117.008150 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH (2017) Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke 48(9):2494–2503.  https://doi.org/10.1161/strokeaha.117.017549 CrossRefPubMedGoogle Scholar
  28. 28.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962.  https://doi.org/10.1016/s0140-6736(13)62343-0 CrossRefPubMedGoogle Scholar
  29. 29.
    Kim IS, Kim HJ, Kim TH, Uhm JS, Joung B, Lee MH, Pak HN (2018) Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: a systematic review and meta-analysis. J Cardiol 72(2):105–112.  https://doi.org/10.1016/j.jjcc.2018.01.015 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Chun-Li Wang
    • 1
    • 2
  • Victor Chien-Chia Wu
    • 1
    • 2
  • Cheng-Hung Lee
    • 1
    • 2
  • Chang-Fu Kuo
    • 2
    • 3
    • 4
  • Yu-Ling Chen
    • 5
  • Pao-Hsien Chu
    • 1
    • 2
  • Shao-Wei Chen
    • 2
    • 6
  • Ming-Shien Wen
    • 1
    • 2
  • Lai-Chu See
    • 3
    • 7
    • 8
  • Shang-Hung Chang
    • 1
    • 2
    • 5
    • 9
    Email author
  1. 1.Cardiovascular Division, Department of Internal MedicineChang Gung Memorial Hospital, Linkou Medical CenterTaoyuanTaiwan
  2. 2.College of MedicineChang Gung UniversityTaoyuanTaiwan
  3. 3.Division of Rheumatology, Allergy and Immunology, Department of Internal MedicineChang Gung Memorial Hospital, Linkou Medical CenterTaoyuanTaiwan
  4. 4.Division of Rheumatology, Orthopaedics and Dermatology, School of MedicineUniversity of NottinghamNottinghamUK
  5. 5.Center for Big Data Analytics and StatisticsChang Gung Memorial Hospital, Linkou Medical CenterTaoyuanTaiwan
  6. 6.Division of Thoracic and Cardiovascular Surgery, Department of SurgeryChang Gung Memorial Hospital, Linkou Medical CenterTaoyuanTaiwan
  7. 7.Department of Public Health, College of MedicineChang Gung UniversityTaoyuanTaiwan
  8. 8.Biostatstics Core Laboratory, Molecular Medicine Research CenterChang Gung UniversityTaoyuanTaiwan
  9. 9.Graduate Institute of NursingChang Gung University of Science and TechnologyTaoyuanTaiwan

Personalised recommendations